Year: 2025
Type: article
Study design: Observational Study
Abstract: Low-density lipoprotein-cholesterol (LDL-C) is a causal modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), and evolocumab—a proprotein subtilisin/kexin type 9 (PCSK9) inhibitor monoclonal antibody—is effective in substantially decreasing LDL-C concentrations. However, many patients who might benefit from PCSK9 inhibitor treatment as per current guideline recommendations will not receive it. Our study aimed to assess patient and physician satisfaction with evolocumab, including perceptions of treatment experience and effectiveness. The Treatment Satisfaction Questionnaire for Medication (TSQM)-9 (nine items; 7- or 5-point Likert scale responses) evaluated satisfaction in 130 adult patients (50% women) using evolocumab. A separate survey (five items; 5-point Likert scale responses) was developed to evaluate satisfaction in 130 physicians (50% primary care providers, 50% cardiologists) who prescribe evolocumab. Participants were recruited in the USA from pre-existing panels. Samples were stratified by US region (West, South, Northeast, and Midwest). Overall 96.1% of patients (mean age 53 years; 78% white) and 90.8% of physicians (mean age 50 years; 81% male; 63% white) were satisfied to various degrees with evolocumab. Patient reporting described various degrees of satisfaction with the ability of evolocumab to prevent or treat their condition (93.8%), relieve their symptoms (95.3%), and with the time it takes to start working (94.8%). They also found evolocumab convenient (92.3%) and easy to use (94.7%). Physicians were satisfied to various degrees with evolocumab’s ability to control elevated LDL-C (93.1%) and the outcomes observed (94.6%) in their patients. They were also satisfied with evolocumab’s convenience for patients (74.6%), their willingness to take it (79.2%), and its dosing frequency (85.4%). A large majority of patients and physicians reported high satisfaction levels about their experience with evolocumab treatment. This may help inform treatment decisions when choosing lipid-lowering therapy in patients with ASCVD and elevated LDL-C concentrations. Low-density lipoprotein-cholesterol (LDL-C) is a type of blood cholesterol. Elevated LDL-C increases the danger of cardiovascular disease. Evolocumab is a medication that can lower LDL-C. We studied patient and physician satisfaction with evolocumab treatment by giving a survey to 130 adult patients (half female) who take evolocumab. We also developed a separate survey and gave it to 130 physicians (half primary care providers, half cardiologists) who prescribe evolocumab. Participants were from the main geographical areas of the USA (West, South, Northeast, and Midwest). Patients were an average of 53 years of age and 78% were white. Physicians were an average age of 50 years, 81% were male, and 63% were white. Almost all patients (96%) and physicians (91%) were satisfied overall with evolocumab. Nearly all patients were satisfied with how evolocumab prevented or treated their condition (94%) and the way it relieved their symptoms (95%). Most patients were satisfied with the time evolocumab took to start working (95%). Also, 92% of patients found evolocumab convenient and 95% found it easy to use. Most physicians were satisfied with the ability of evolocumab to control elevated LDL-C (93%) and the effects of the treatment seen in their patients (95%). Also, 75% of physicians were mostly satisfied with the convenience of evolocumab for patients, patients’ willingness to take the medication (79%), and dosing frequency (85%). These results may help physicians and patients when they choose among treatments to lower LDL-C in patients with cardiovascular disease.
Source: Advances in Therapy
Institutions: Amgen (Switzerland), Amgen (United States)
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,790
Funder: Amgen
OpenAlex ID: W4413101601